Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Beauty Health’s latest analyst update comes with a trimmed price target, with some bullish researchers moving from US$1.65 to US$1.50 while model fair value holds at US$1.69. That shift lines up with commentary that Q4 outperformance and FY26 EBITDA guidance are being weighed against softer near term distributor orders and execution questions. As you read on, you will see how these mixed signals are shaping the evolving narrative around risk, reward, and what to watch next.
Stay updated as the Fair Value for Beauty Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Beauty Health.
TD Cowen highlights that Q4 revenue, while down, still came in ahead of its expectations. This supports its decision to maintain a Hold rating rather than move more negative on the stock.
The firm points out that Beauty Health’s FY26 EBITDA guidance implies roughly 20% upside versus current Street estimates. Some investors may view this as support for the existing fair value models around US$1.69.
TD Cowen cut its price target from US$1.65 to US$1.50, signaling that the firm sees a more constrained risk reward balance even while keeping its rating unchanged.
The same report flags softer expected performance in 1Q as distributor ordering adjusts to macro pressure. This feeds into ongoing questions around execution and the timing of any improvement in demand trends.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqCM:SKIN 1-Year Stock Price Chart
We’ve flagged 3 risks for Beauty Health. See which could impact your investment.
Beauty Health reported no share repurchases between October 1, 2025 and December 31, 2025. Its buyback program under the September 12, 2023 authorization has totaled 10,350,749 shares, or 7.81%, for US$30.18 million.
The company issued Q1 2026 earnings guidance, projecting net sales between US$63 million and US$68 million.
For full year 2026, Beauty Health guided to net sales in a range of US$285 million to US$305 million, providing clear revenue targets to monitor.
Beauty Health outlined broader use of Hydrafacial treatments with SkinStylus Nano-Channeling and disclosed a proposed settlement of shareholder derivative claims in Delaware Chancery Court that includes corporate governance reforms, with a hearing set for May 13, 2026.
Story Continues
Fair value: Model fair value remains at US$1.69, with no change to the valuation anchor.
Revenue growth: Revenue growth assumption is effectively unchanged at 2.30%.
Net profit margin: Net profit margin assumption moves from 4.13% to 4.28%.
P/E ratio: Future P/E multiple shifts from 23.48x to 23.16x.
Discount rate: The discount rate adjusts from 11.55% to 12.33%.
Narratives link a company’s real world story to a financial forecast and fair value so you can see how key assumptions fit together. They refresh as new data, guidance, and risks come through, giving you a living view of the thesis.
Head over to the Simply Wall St Community and follow the Narrative on Beauty Health to stay up to date on:
How Beauty Health’s reliance on premium Hydrafacial treatments and devices shapes its exposure to changing consumer tastes and competitive pressure from both global brands and indie players.
The role of consumables driven recurring revenue, product launches like new Hydrafacial boosters, and an installed base of more than 35,000 devices across regions such as the Americas and EMEA.
How factors such as tighter environmental and safety regulation, macro pressure on discretionary beauty spending, and new at home or digital skin care options could affect demand and margins over time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SKIN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
